Concepedia

Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study

Livia Lontai, Lóránt Gönczi, F Balogh, Nóra Komlódi, Tamás Resál, Klaudia Farkas, Tamás Molnár, Pál Miheller, Petra A. Golovics, Eszter Schäfer,

Digestive and Liver Disease · 2022 · 17 citations · 20 references

DOIFull text

Open access

Concepts

References

20

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

Jack Satsangi · Gut · 2006 · 3.2K citations · Full text

, , +16

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

, , +11

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

Mirthe E. van der Valk, Marie‐Josée J. Mangen, Max Leenders et al. · Gut · 2012 · 498 citations · Full text

, , +17

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

Silvio Danese, Gionata Fiorino, Tim Raine et al. · Journal of Crohn s and Colitis · 2016 · 240 citations · Full text

, , +11

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Byong Duk Ye, Marina Pesegova, Olga Alexeeva et al. · The Lancet · 2019 · 209 citations · Full text

, , +11